Skip to main content
Erschienen in: Diabetologia 9/2005

01.09.2005 | Article

Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors

verfasst von: A. M. Hennige, V. Strack, E. Metzinger, G. Seipke, H.-U. Häring, M. Kellerer

Erschienen in: Diabetologia | Ausgabe 9/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

New insulin analogues have been created by amino-acid exchange to provide an improved pharmacokinetic profile. However, safety issues have been raised regarding their use, as amino-acid exchange of insulin may induce altered metabolic and mitogenic effects. For example, the insulin analogue Asp(B10) causes breast cancer in rodents. The aim of this study was to compare two new insulin analogues HMR1964 (Lys[B3],Glu[B29]) (insulin glulisine) and HMR1423 (Gly[A21],His[B31],His[B32]) with regular insulin and the mitogenic analogue Asp(B10).

Materials and methods

We analysed insulin receptor binding characteristics and dissociation kinetics, as well as insulin-induced receptor auto- and dephosphorylation kinetics, in rat-1 fibroblasts overexpressing the human insulin receptor isoform B. Mitogenic activity was tested in the non-malignant cell line MCF10.

Results

Regular insulin, HMR1964 and HMR1423 showed no significant differences in receptor association, dissociation and receptor binding affinity, while Asp(B10) displayed markedly increased insulin receptor affinity. All of the analogues induced rapid insulin receptor autophosphorylation, reaching a maximum 10 min after stimulation (10−9 mmol/l insulin). In contrast, Asp(B10) induced a prolonged phosphorylation and dephosphorylation state of the 95 kDa insulin receptor β-subunit. With respect to [3H]thymidine incorporation, the new analogues had similar (HMR1423) or even lower (HMR1964) effects than regular insulin in the mammary epithelial cell line MCF10, while Asp(B10) showed increased [3H]thymidine incorporation.

Conclusions/interpretation

HMR1964 and HMR1423 displayed the same association, dissociation and insulin receptor affinity kinetics as regular insulin, and might therefore be useful for the treatment of diabetes.
Literatur
1.
Zurück zum Zitat Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA (1999) Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42:1151–1167CrossRefPubMed Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA (1999) Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42:1151–1167CrossRefPubMed
2.
Zurück zum Zitat Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396–402PubMed Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396–402PubMed
3.
Zurück zum Zitat Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time–action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649PubMed Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time–action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649PubMed
4.
Zurück zum Zitat Setter SM, Corbett CF, Campbell RK, White JR (2000) Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 34:1423–1431PubMed Setter SM, Corbett CF, Campbell RK, White JR (2000) Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 34:1423–1431PubMed
5.
Zurück zum Zitat Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMed Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMed
6.
Zurück zum Zitat Schwartz GP, Burke GT, Katsoyannis PG (1987) A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci U S A 84:6408–6411PubMed Schwartz GP, Burke GT, Katsoyannis PG (1987) A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci U S A 84:6408–6411PubMed
7.
Zurück zum Zitat Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S, Gammeltoft S (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488–1495PubMed Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S, Gammeltoft S (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488–1495PubMed
8.
Zurück zum Zitat Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313PubMed Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313PubMed
9.
Zurück zum Zitat Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC (1999) Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism 48:611–617CrossRefPubMed Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC (1999) Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism 48:611–617CrossRefPubMed
10.
Zurück zum Zitat Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU (1998) The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123–129PubMed Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU (1998) The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123–129PubMed
11.
Zurück zum Zitat Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40:54–61CrossRef Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40:54–61CrossRef
12.
Zurück zum Zitat Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259–285PubMed Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259–285PubMed
13.
Zurück zum Zitat Soule HD, Maloney TM, Wolman SR et al (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF10. Cancer Res 50:6075–6086PubMed Soule HD, Maloney TM, Wolman SR et al (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF10. Cancer Res 50:6075–6086PubMed
14.
Zurück zum Zitat Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18:19–25CrossRefPubMed Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18:19–25CrossRefPubMed
15.
Zurück zum Zitat Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMed Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMed
16.
Zurück zum Zitat Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–279PubMed Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–279PubMed
17.
Zurück zum Zitat Denley A, Wallace JC, Cosgrove LJ, Forbes BE (2003) The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 35:778–785CrossRefPubMed Denley A, Wallace JC, Cosgrove LJ, Forbes BE (2003) The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 35:778–785CrossRefPubMed
18.
Zurück zum Zitat Rakatzi I, Ramrath S, Ledwig D et al (2003) A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52:2227–2238PubMed Rakatzi I, Ramrath S, Ledwig D et al (2003) A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52:2227–2238PubMed
Metadaten
Titel
Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors
verfasst von
A. M. Hennige
V. Strack
E. Metzinger
G. Seipke
H.-U. Häring
M. Kellerer
Publikationsdatum
01.09.2005
Erschienen in
Diabetologia / Ausgabe 9/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1870-8

Weitere Artikel der Ausgabe 9/2005

Diabetologia 9/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.